Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.
AuthorsBarrington, S F
Somer, E J
Radford, John A
O'Doherty, M J
AffiliationPET Imaging Centre at St Thomas', Kings College London Division of Imaging, Lambeth Palace Road, London SE1 7EH, UK. email@example.com
MetadataShow full item record
AbstractPURPOSE: To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. METHODS: Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). RESULTS: There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. CONCLUSION: The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.
CitationConcordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. 2010, 37 (10):1824-33 Eur. J Nucl Med Mol Imaging
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
- International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
- Authors: Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF
- Issue date: 2013 May
- Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.
- Authors: Barrington SF, MacKewn JE, Schleyer P, Marsden PK, Mikhaeel NG, Qian W, Mouncey P, Patrick P, Popova B, Johnson P, Radford J, O'Doherty MJ
- Issue date: 2011 Mar
- Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
- Authors: Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N
- Issue date: 2015 Jan 9
- Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
- Authors: Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O
- Issue date: 2017 Sep
- Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
- Authors: Anderson RA, Remedios R, Kirkwood AA, Patrick P, Stevens L, Clifton-Hadley L, Roberts T, Hatton C, Kalakonda N, Milligan DW, McKay P, Rowntree C, Scott FM, Johnson PWM
- Issue date: 2018 Oct